Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (181-190 of 362) with videos related to

Pageof 37
Sort By:
EJNMMI Research|August 21, 2021
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imagingCarol Oliveira, Florian Amstutz, Diem Vuong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Cancer|August 9, 2024
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences studyVladimir Jolidon, Manuela Eicher, Isabelle Peytremann-Bridevaux, et al.
British Journal of Cancer|June 12, 2024
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinomaJan Budczies, Eva Romanovsky, Martina Kirchner, et al.
British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2018
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use ProgramSolange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, et al.
Cold Spring Harbor Molecular Case Studies|January 21, 2022
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case reportMarkus Ball, Petros Christopoulos, Martina Kirchner, et al.
British Journal of Cancer|April 17, 2019
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)Alessandra Curioni-Fontecedro, Jean Yannis Perentes, Hans Gelpke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
Pageof 37

Showing results (181-190 of 362) with videos related to

Sort By:
Pageof 37
EJNMMI Research|August 21, 2021
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imagingCarol Oliveira, Florian Amstutz, Diem Vuong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Cancer|August 9, 2024
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences studyVladimir Jolidon, Manuela Eicher, Isabelle Peytremann-Bridevaux, et al.
British Journal of Cancer|June 12, 2024
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinomaJan Budczies, Eva Romanovsky, Martina Kirchner, et al.
British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2018
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use ProgramSolange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, et al.
Cold Spring Harbor Molecular Case Studies|January 21, 2022
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case reportMarkus Ball, Petros Christopoulos, Martina Kirchner, et al.
British Journal of Cancer|April 17, 2019
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)Alessandra Curioni-Fontecedro, Jean Yannis Perentes, Hans Gelpke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
Pageof 37